Chroma Medicine is pioneering a new class of genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, revolutionizing the treatment of genetically driven diseases.
The epigenome is nature’s gatekeeper for gene expression, governing cell phenotype and function by precisely controlling gene activity without changing the underlying DNA sequence. Building on groundbreaking research from the world’s foremost genomic medicine experts, Chroma Medicine is working at the cutting edge of precision genomics, building an entirely new class of therapeutics to achieve unparalleled control of gene expression.
The epigenome is nature’s gatekeeper for gene expression, governing cell phenotype and function by precisely controlling gene activity without changing the underlying DNA sequence. Building on groundbreaking research from the world’s foremost genomic medicine experts, Chroma Medicine is working at the cutting edge of precision genomics, building an entirely new class of therapeutics to achieve unparalleled control of gene expression.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $260M
Founded date: 2021
Investors 5
| Date | Name | Website |
| 21.02.2023 | DCVC | dcvc.com/ |
| 08.11.2023 | ARCH Ventu... | archventur... |
| 15.01.2022 | Omega Fund... | omegafunds... |
| 18.11.2021 | Atlas Vent... | atlasventu... |
| - | Newpath Ma... | newpath.pa... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.03.2023 | Series B | $135M | Janus Hend... |
| 17.11.2021 | - | $125M | - |
Mentions in press and media 10
| Date | Title | Description |
| 14.12.2024 | The Rise of nChroma Bio: A New Dawn in Genetic Medicine | In the world of biotechnology, mergers and funding are the lifeblood of innovation. Recently, two companies, Chroma Medicine and Nvelop Therapeutics, joined forces to create nChroma Bio. This new entity is set to redefine the landscape of g... |
| 12.12.2024 | Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio and Raises $75M | Biotechnology companies Chroma Medicine (Boston, MA) and Nvelop Therapeutics (Cambridge, MA) announced their merger and subsequent launch of nChroma Bio to expand the R&D of the genetic medicines sector. Concurrent with the merger, nChr... |
| 03.09.2024 | Chroma Medicine Presents Preclinical In Vivo Data Demonstrating Best-in-Class Potency and Durable Cholesterol Reduction with a PCSK9-Targeted Epigenetic Editor at the 2024 ESC Congress | New NHP data indicate robust silencing at clinically relevant dose levels and highlight potential best-in-class potency achievable with Chroma's epigenetic editors Chroma's epigenetic editor achieved efficient and durable reductions in bloo... |
| 27.06.2024 | Chroma Medicine Announces Exclusive License Agreement with the Whitehead Institute for Novel Epigenetic Editing Technology | License provides exclusive access to innovative epigenetic editors and expands the reach of Chroma's platform BOSTON, June 27, 2024 /PRNewswire/ -- Chroma Medicine, Inc. (Chroma) a genomic medicine company pioneering single-course epigeneti... |
| 01.03.2023 | Chroma Medicine Raises $135M in Series B Financing | Chroma Medicine, a Cambridge, MA-based genomic medicine company, raised $135M in Series B funding. The round was led by GV, with participation from additional new investors ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, an... |
| 01.03.2023 | Chroma Medicine Secures $135M in Series B | CAMBRIDGE, MA, Chroma Medicine announces the completion of a $135 million Series B financing led by GV (Google Ventures). >> Click here for more funding data on Chroma Medicine >> To export Chroma Medicine funding data to PD... |
| 19.11.2021 | Neo-bank Dave’s CEO thinks traditional banks are ‘in a pickle’ | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Good morning—this is Fortune reporter Rey Mashayekhi, filling in for Lucinda. Paid Content How A.... |
| 19.11.2021 | Neo-bank Dave’s CEO thinks traditional banks are ‘in a pickle’ | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Good morning—this is Fortune reporter Rey Mashayekhi, filling in for Lucinda. Paid Content This c... |
| 17.11.2021 | Chroma Medicine Launches with $125M in Financing to Deliver on the Promise of Epigenetic Editing | CAMBRIDGE, Mass., Nov. 17, 2021 /PRNewswire/ -- Chroma Medicine, Inc., (Chroma) a new genomic medicine company pioneering epigenetic editing, launched today with $125M in financing. Atlas Venture and Newpath Partners seeded the company with... |
| - | Chroma Medicine | “Chroma Medicine is pioneering a new class of epigenetic medicines to revolutionize treatment of genetically driven disease.” |